Will Obesity Drugs Save Pfizer From Its Post-COVID Slump?

Why It Matters

Obesity therapeutics represent a multi‑billion‑dollar market that could replace dwindling COVID‑19 and blockbuster revenues, reshaping Pfizer’s long‑term earnings profile. A breakthrough in this space would also restore investor confidence in Pfizer’s innovation pipeline.

Key Takeaways

• Pfizer faces $1.5 billion revenue headwind from patent expirations
• Obesity market projected to exceed $100 billion by 2030
• Pfizer spent $10 billion acquiring Metsera to enter weight‑loss space
• New obesity assets aim for FDA approval by 2028
• Berobenatide showed 12.3% weight loss in 28‑week study

Pulse Analysis

Pfizer’s earnings outlook has been reshaped by the rapid decline of its COVID‑19 products and looming patent cliffs on legacy blockbusters such as Eliquis, Xeljanz and Prevnar 13. The company now anticipates a $1.5 billion revenue shortfall this year, potentially expanding to $4.5 billion by 2027, prompting a strategic pivot toward high‑growth therapeutic areas. By allocating over $80 billion to acquisitions and licensing, Pfizer is betting that a robust obesity portfolio can fill the gap and re‑ignite top‑line momentum.

The centerpiece of this pivot is the $10 billion Metsera acquisition, which adds four clinical‑stage candidates and positions Pfizer in a weight‑loss market projected to surpass $100 billion by 2030. Complementary deals—including a $2.1 billion licensing agreement with YaoPharma for an oral GLP‑1 pill and a $495 million stake in Sciwind’s injectable GLP‑1 agonist—expand the company’s modality mix and geographic reach. These assets collectively target a first FDA filing by 2028, with the potential to generate $20 billion in revenue by 2030 if they achieve best‑in‑class efficacy.

If Pfizer’s obesity drugs succeed, the company could offset the erosion of its traditional revenue streams and restore its reputation as an innovation leader. The clinical data for berobenatide, which delivered a 12.3% weight loss after 28 weeks, underscores the therapeutic promise and the importance of differentiated dosing regimens such as monthly or quarterly injections. Ultimately, the ability to commercialize a blockbuster obesity therapy will be a decisive factor in whether Pfizer can transition from a post‑COVID slump to sustainable growth in the next decade.